An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor

Chest

Volumn 143, Issue 5, 2013, Pages 1478-1479

  Wysham, Nicholas G ^a   Sullivan, Donald R ^b   Allada, Gopal ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUCONAZOLE; PREDNISONE; RUXOLITINIB;

AGED; ANTIFUNGAL ACTIVITY; ARTICLE; BONE PAIN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CRYPTOCOCCUS NEOFORMANS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FIBEROPTIC BRONCHOSCOPY; FUNGUS CULTURE; HUMAN; LEUKOCYTOSIS; LOADING DRUG DOSE; MALE; MYELOFIBROSIS; NONHUMAN; OPPORTUNISTIC INFECTION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 84877618100     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1604     Document Type: Article

References (6)

1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofi brosis. N Engl J Med. 2012;366(9):799-807.
2. Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol. 2011;29(6):467-468.
3. Sandborn WJ, Ghosh S, Panes J, et al; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616-624.
4. Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med. 2012;366(9):844-846.
5. Voelz K, May RC. Cryptococcal interactions with the host immune system. Eukaryot Cell. 2010;9(6):835-846.
6. Salmon-Ceron D, Tubach F, Lortholary O, et al; RATIO group. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616-623.